Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.

Cancer Discovery
Timothy A YapJohann S de Bono

Abstract

Preclinical studies have demonstrated synergy between PARP and PI3K/AKT pathway inhibitors in BRCA1 and BRCA2 (BRCA1/2)-deficient and BRCA1/2-proficient tumors. We conducted an investigator-initiated phase I trial utilizing a prospective intrapatient dose- escalation design to assess two schedules of capivasertib (AKT inhibitor) with olaparib (PARP inhibitor) in 64 patients with advanced solid tumors. Dose expansions enrolled germline BRCA1/2-mutant tumors, or BRCA1/2 wild-type cancers harboring somatic DNA damage response (DDR) or PI3K-AKT pathway alterations. The combination was well tolerated. Recommended phase II doses for the two schedules were: olaparib 300 mg twice a day with either capivasertib 400 mg twice a day 4 days on, 3 days off, or capivasertib 640 mg twice a day 2 days on, 5 days off. Pharmacokinetics were dose proportional. Pharmacodynamic studies confirmed phosphorylated (p) GSK3β suppression, increased pERK, and decreased BRCA1 expression. Twenty-five (44.6%) of 56 evaluable patients achieved clinical benefit (RECIST complete response/partial response or stable disease ≥ 4 months), including patients with tumors harboring germline BRCA1/2 mutations and BRCA1/2 wild-type cancers with or without DDR and PI3K-AK...Continue Reading

References

Jul 20, 2007·Assay and Drug Development Technologies·Sharon M GowanSuzanne A Eccles
Nov 14, 2012·Cancer Discovery·Farah L RehmanAlan Ashworth
Jun 29, 2015·Current Opinion in Pharmacology·Timothy A YapPaul Workman
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Nov 8, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Wei MoShiaw-Yih Lin
Mar 5, 2016·Cancer Chemotherapy and Pharmacology·Kenji TamuraTaito Esaki
Dec 23, 2016·Cancer Discovery·Jessica S BrownTimothy A Yap
Apr 30, 2017·Cancer Discovery·Jane GoodallUNKNOWN TOPARP-A investigators
May 11, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David M HymanBarry S Taylor
Jun 6, 2017·The New England Journal of Medicine·Mark RobsonPierfranco Conte
Aug 13, 2017·Cell·David A FrumanRobert T Abraham
Oct 27, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Udai BanerjiJan H M Schellens
Nov 23, 2017·Nucleic Acids Research·Melissa J LandrumDonna R Maglott
Aug 16, 2018·The New England Journal of Medicine·Jennifer K LittonJoanne L Blum
Oct 23, 2018·The New England Journal of Medicine·Kathleen MoorePaul DiSilvestro
Oct 26, 2018·Nature Reviews. Clinical Oncology·Patrick G PiliéTimothy A Yap
Oct 31, 2018·Bioinformatics·Christos KopanosAndreas Massouras
Feb 15, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patrick G PiliéTimothy A Yap
Jun 4, 2019·The New England Journal of Medicine·Talia GolanHedy L Kindler

❮ Previous
Next ❯

Citations

Dec 15, 2020·Current Opinion in Obstetrics & Gynecology·Emily HinchcliffShannon N Westin
Dec 21, 2020·Genes, Chromosomes & Cancer·Hans Martin SinghChristoph Springfeld
Oct 28, 2020·Cells·Daniel J TurnhamHelen B Pearson
Oct 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L TobalinaJ V Forment
May 18, 2021·Frontiers in Pharmacology·Federica MartoranaPaolo Vigneri
Aug 1, 2021·Cancer Treatment Reviews·Hélène VanackerIsabelle Ray-Coquard
Jul 22, 2021·Nature Reviews. Clinical Oncology·Mariana Paes DiasJos Jonkers
Aug 7, 2021·Biomolecules·Chao-Lien LiuTsui-Lien Mao
Oct 5, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P G PiliéT A Yap
Sep 15, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shannon N WestinGordon B Mills
Sep 29, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·E Gabriela ChioreanHoward S Hochster

❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.